Financial reports
10-K
2023 FY
Annual report
19 Mar 24
10-Q
2023 Q3
Quarterly report
7 Nov 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
10-Q
2023 Q1
Quarterly report
9 May 23
ARS
2022 FY
Annual report to shareholders
1 May 23
10-K
2022 FY
Annual report
7 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
8 Aug 22
10-Q
2022 Q1
Quarterly report
16 May 22
10-K
2021 FY
Annual report
7 Mar 22
Current reports
8-K
Scholar Rock Reports Full Year 2023 Financial Results and Highlights Business Progress
19 Mar 24
8-K
Scholar Rock Announces the Addition of Katie Peng to Its Board of Directors and Promotes Mo Qatanani, Ph.D. to Chief Scientific Officer
15 Feb 24
8-K
Results of Operations and Financial Condition
8 Jan 24
8-K
Results of Operations and Financial Condition
7 Nov 23
8-K
Scholar Rock Announces Proposed Public Offering of Common Stock
12 Oct 23
8-K
Scholar Rock TO ADVANCE ANTIMYOSTATIN PROGRAM to develop novel therapies for CARDIOMETABOLIC DISORDERS
11 Oct 23
8-K
Results of Operations and Financial Condition
9 Aug 23
8-K
Regulation FD Disclosure
30 Jun 23
8-K
Submission of Matters to a Vote of Security Holders
22 Jun 23
8-K
Results of Operations and Financial Condition
9 May 23
Registration and prospectus
S-8
Registration of securities for employees
19 Mar 24
424B5
Prospectus supplement for primary offering
12 Oct 23
424B5
Prospectus supplement for primary offering
11 Oct 23
S-8
Registration of securities for employees
7 Mar 23
S-3
Shelf registration
14 Nov 22
S-8
Registration of securities for employees
14 Nov 22
S-8
Registration of securities for employees
8 Aug 22
424B5
Prospectus supplement for primary offering
21 Jun 22
S-8
Registration of securities for employees
7 Mar 22
POS AM
Prospectus update (post-effective amendment)
7 Mar 22
Proxies
PRE 14A
Preliminary proxy
17 Apr 24
DEFA14A
Additional proxy soliciting materials
1 May 23
DEF 14A
Definitive proxy
1 May 23
DEFA14A
Additional proxy soliciting materials
13 Apr 22
DEF 14A
Definitive proxy
13 Apr 22
DEF 14A
Definitive proxy
15 Apr 21
DEF 14A
Definitive proxy
23 Apr 20
DEF 14A
Definitive proxy
30 Apr 19
Other
EFFECT
Notice of effectiveness
28 Nov 22
CORRESP
Correspondence with SEC
22 Nov 22
UPLOAD
Letter from SEC
21 Nov 22
EFFECT
Notice of effectiveness
14 Apr 22
EFFECT
Notice of effectiveness
11 Jun 19
CT ORDER
Confidential treatment order
6 Jun 19
CORRESP
Correspondence with SEC
6 Jun 19
UPLOAD
Letter from SEC
6 Jun 19
CT ORDER
Confidential treatment order
4 Mar 19
EFFECT
Notice of effectiveness
24 May 18
Ownership
4
Katie Peng
11 Apr 24
4
Edward H Myles
21 Feb 24
4
Mo Qatanani
20 Feb 24
4
Caryn Parlavecchio
20 Feb 24
4
Junlin Ho
20 Feb 24
4
Jay T. Backstrom
20 Feb 24
3
Katie Peng
15 Feb 24
SC 13G
ORBIMED ADVISORS LLC
14 Feb 24
SC 13G/A
Redmile Group, LLC
14 Feb 24
SC 13G/A
ARCH Venture Fund VIII, L.P.
14 Feb 24